The Jury’s Still Out on Victoza
Novo Nordisk is well-known in the diabetes community for its insulins, Novolog and Levemir, used to treat mainly type 1 diabetes. But in the last year, Novo launched a new kind of injectable, a “first line of defense for people with type 2 diabetes” called Victoza (generic: liraglutide). It’s a glucagon-like peptide-1 (GLP-1) drug designed
Read the rest here:
The Jury’s Still Out on Victoza
Mail this post
Transforming Health Care, Today
Today I am in Rochester, MN, at the world-famous Mayo Clinic, taking in part in a “collaborative symposium” on health care called Transform. David Rosenman, a physician who runs the Mayo’s new Center for Innovation, had the idea to gather a bunch of smart, engaged people to exchange ideas on “new models of health care.” This
Original post:
Transforming Health Care, Today
Mail this post
What a New Era of Pharma Marketing Means to (Diabetes) Patients
As you may have noticed, I’m fascinated with where new Web-enabled communication tools are taking us in the world of medicine in healthcare. I’m also a huge admirer of the work of the outspoken and sage John Mack, publisher of Pharma Marketing News and author of the Pharma Marketing Blog. I was therefore delighted when
Original post:
What a New Era of Pharma Marketing Means to (Diabetes) Patients
Mail this post